Jackson Health System Gynecologic Oncology

Topics

• Endometrial and Cervical Cancer Treatments 329
• Ovarian cancer diagnosis and treatment 297
• Cervical Cancer and HPV Research 171
• Uterine Myomas and Treatments 51
• Pelvic floor disorders treatments 29
• Cancer survivorship and care 24
• BRCA gene mutations in cancer 20
• Ureteral procedures and complications 20
• Sarcoma Diagnosis and Treatment 19
• Cancer Risks and Factors 18
• HER2/EGFR in Cancer Research 18
• Endometriosis Research and Treatment 17

Most cited

1. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

   The New England journal of medicine · 2023 · 633 citations · Guilherme Cantuaria

2. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

   The New England journal of medicine · 2023 · 405 citations · Michael Method

3. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 323 citations · Joseph De La Garza

4. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 350 citations · Michael Method

5. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.

   Nature medicine · 2025 · 59 citations · Guilherme Cantuaria

6. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.